Cefuroxime-AFT

Nazione: Nuova Zelanda

Lingua: inglese

Fonte: Medsafe (Medicines Safety Authority)

Principio attivo:

Cefuroxime sodium 1578mg equivalent to 1500 mg cefuroxime;  

Commercializzato da:

AFT Pharmaceuticals Ltd

INN (Nome Internazionale):

Cefuroxime sodium 1578 mg (equivalent to 1500 mg cefuroxime)

Dosaggio:

1.5 g

Forma farmaceutica:

Powder for injection

Composizione:

Active: Cefuroxime sodium 1578mg equivalent to 1500 mg cefuroxime  

Confezione:

Vial, glass, Type I, 20mL with rubber septum, 1 dose unit

Classe:

Prescription

Tipo di ricetta:

Prescription

Prodotto da:

Qilu Antibiotics Pharmaceutical Co Ltd

Indicazioni terapeutiche:

CEFUROXIME-AFT is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. Indications include: · Respiratory tract infections e.g. acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections.

Dettagli prodotto:

Package - Contents - Shelf Life: Vial, glass, Type I, 20mL with rubber septum - 1 dose units - 24 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) - Vial, glass, Type 1, 20mL with rubber septum 10's - 10 dose units - 24 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze)

Data dell'autorizzazione:

2010-07-26

Scheda tecnica

1
NEW ZEALAND DATA SHEET
1.
PRODUCT NAME
CEFUROXIME-AFT 250 mg contains Cefuroxime sodium equivalent to
Cefuroxime 250 mg.
CEFUROXIME-AFT 750 mg contains Cefuroxime sodium equivalent to
Cefuroxime 750 mg.
CEFUROXIME-AFT 1.5 g contains Cefuroxime sodium equivalent to
Cefuroxime 1.5 g.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
CEFUROXIME-AFT injection contains either, 250 mg 750 mg, or 1.5 g of
cefuroxime. Each 750
mg vial contains 41 mg sodium
.
For full list of excipients, see Section 6.1 List of Excipients.
3.
PHARMACEUTICALFORM
Powder for injection.
4.
CLINICALPARTICULARS
4.1
THERAPEUTIC INDICATIONS
Cefuroxime is a bactericidal cephalosporin antibiotic which is
resistant to most β-lactamases and
is active against a wide range of Gram-positive and Gram-negative
organisms.
It is indicated for the treatment of infections before the infecting
organism has been identified
or when caused by sensitive bacteria. Susceptibility to cefuroxime
sodium will vary with
geography and time and local susceptibility data should be consulted
where available (see
Section 5.1 Pharmacodynamic properties).
Indications include:
•
Respiratory
tract
infections
for
example,
acute
and
chronic
bronchitis,
infected
bronchiectasis, bacterial pneumonia, lung abscess and post-operative
chest infections.
•
Ear, nose and throat infections for example, sinusitis, tonsillitis,
pharyngitis and otitis
media.
•
Urinary tract infections for example, acute and chronic
pyelonephritis, cystitis and
asymptomatic bacteriuria.
•
Soft-tissue infections for example, cellulitis, erysipelas and wound
infections.
•
Bone and joint infections for example, osteomyelitis and septic
arthritis.
•
Obstetric and gynaecological infections, pelvic inflammatory diseases.
•
Gonorrhoea particularly when penicillin is unsuitable.
•
Other infections including septicaemia, meningitis and peritonitis.
•
Prophylaxis against infection in abdominal, pelvic, orthopaedic,
cardiac, pulmonary,
oesophageal and vascular surgery where there is increased risk from
infec